SANA
NASDAQ · Biotechnology
Sana Biotechnology Inc
$3.15
+0.11 (+3.62%)
Open$3.10
Previous Close$3.04
Day High$3.20
Day Low$3.03
52W High$6.55
52W Low$2.58
Volume—
Avg Volume4.25M
Market Cap876.62M
P/E Ratio—
EPS$-0.94
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,172.4% upside
Current
$3.15
$3.15
Target
$40.08
$40.08
$23.55
$40.08 avg
$57.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 204.77M | 187.81M | 190.12M |
| Net Income | 17.06M | 14.80M | 14.99M |
| Profit Margin | 8.3% | 7.9% | 7.9% |
| EBITDA | 24.96M | 25.10M | 25.01M |
| Free Cash Flow | 20.72M | 16.56M | 17.82M |
| Rev Growth | +11.7% | +19.4% | -6.7% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |